• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Dicerna Pharmaceuticals, Inc.

    12/3/21 6:09:54 AM ET
    $DRNA
    Major Pharmaceuticals
    Health Care
    Get the next $DRNA alert in real time by email
    SC 13G 1 d161089dsc13g.htm SC 13G SC 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

     

     

    Dicerna Pharmaceuticals Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    253031108

    (CUSIP Number)

    November 23, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 253031108    Page 2 of 29 Pages

     

      1    

      NAMES OF REPORTING PERSONS

     

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

     

      Atlas Diversified Master Fund, Ltd.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

          Cayman

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

          4,408,952 (See Item 4)

       6   

      SHARED VOTING POWER

     

          None (see Item 4)

       7   

      SOLE DISPOSITIVE POWER

     

          4,408,952 (See Item 4)

       8   

      SHARED DISPOSITIVE POWER

     

          None

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

          4,408,952 (See Item 4)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

          ☐

     

          Not Applicable

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

          5.67%

    12  

      TYPE OF REPORTING PERSON*

     

          CO

    *SEE INSTRUCTIONS BEFORE FILLING OUT.


    CUSIP No. 253031108    Page 3 of 29 Pages

     

      1    

      NAMES OF REPORTING PERSONS

     

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

     

      Atlas Diversified Fund, Ltd.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Cayman

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

          4,408,952 (See Item 4)

       6   

      SHARED VOTING POWER

     

          None (see Item 4)

       7   

      SOLE DISPOSITIVE POWER

     

          4,408,952 (See Item 4)

       8   

      SHARED DISPOSITIVE POWER

     

          None

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

          4,408,952 (See Item 4)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

          ☐

     

          Not Applicable

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

          5.67%

    12  

      TYPE OF REPORTING PERSON*

     

          CO

    *SEE INSTRUCTIONS BEFORE FILLING OUT.


    CUSIP No. 253031108    Page 4 of 29 Pages

     

      1    

      NAMES OF REPORTING PERSONS

     

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

     

      Atlas Diversified Fund, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Cayman

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

          4,408,952 (See Item 4)

       6   

      SHARED VOTING POWER

     

          None (see Item 4)

       7   

      SOLE DISPOSITIVE POWER

     

          4,408,952 (See Item 4)

       8   

      SHARED DISPOSITIVE POWER

     

          None

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

          4,408,952 (See Item 4)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

          ☐

     

          Not Applicable

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

          5.67%

    12  

      TYPE OF REPORTING PERSON*

     

          PN

    *SEE INSTRUCTIONS BEFORE FILLING OUT.


    CUSIP No. 253031108    Page 5 of 29 Pages

     

      1    

      NAMES OF REPORTING PERSONS

     

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

     

      Atlas Enhanced Master Fund, Ltd.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Cayman

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

          3,997,346

       6   

      SHARED VOTING POWER

     

          None (See Item 4)

       7   

      SOLE DISPOSITIVE POWER

     

          3,997,346

       8   

      SHARED DISPOSITIVE POWER

     

          None (See Item 4)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

          3,997,346 (See Item 4)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

          ☐

     

          Not Applicable

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

          5.14%

    12  

      TYPE OF REPORTING PERSON*

     

          CO

    *SEE INSTRUCTIONS BEFORE FILLING OUT.


    CUSIP No. 253031108    Page 6 of 29 Pages

     

      1    

      NAMES OF REPORTING PERSONS

     

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

     

      Atlas Enhanced Fund, Ltd.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Cayman

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

          3,997,346

       6   

      SHARED VOTING POWER

     

          None (See Item 4)

       7   

      SOLE DISPOSITIVE POWER

     

          3,997,346

       8   

      SHARED DISPOSITIVE POWER

     

          None (See Item 4)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

          3,997,346 (See Item 4)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

          ☐

     

          Not Applicable

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

          5.14%

    12  

      TYPE OF REPORTING PERSON*

     

          CO

    *SEE INSTRUCTIONS BEFORE FILLING OUT.


    CUSIP No. 253031108    Page 7 of 29 Pages

     

      1    

      NAMES OF REPORTING PERSONS

     

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

     

      Atlas Enhanced Fund, LP

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

          3,997,346

       6   

      SHARED VOTING POWER

     

          None (See Item 4)

       7   

      SOLE DISPOSITIVE POWER

     

          3,997,346

       8   

      SHARED DISPOSITIVE POWER

     

          None (See Item 4)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

          3,997,346 (See Item 4)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

          ☐

     

          Not Applicable

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

          5.14%

    12  

      TYPE OF REPORTING PERSON*

     

          PN

    *SEE INSTRUCTIONS BEFORE FILLING OUT.


    CUSIP No. 253031108    Page 8 of 29 Pages

     

      1    

      NAMES OF REPORTING PERSONS

     

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

     

      Atlas Portable Alpha, LP

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

          3,997,346

       6   

      SHARED VOTING POWER

     

          None (See Item 4)

       7   

      SOLE DISPOSITIVE POWER

     

          3,997,346

       8   

      SHARED DISPOSITIVE POWER

     

          None (See Item 4)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

          3,997,346 (See Item 4)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

          ☐

     

          Not Applicable

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

          5.14%

    12  

      TYPE OF REPORTING PERSON*

     

          PN

    *SEE INSTRUCTIONS BEFORE FILLING OUT.


    CUSIP No. 253031108    Page 9 of 29 Pages

     

      1    

      NAMES OF REPORTING PERSONS

     

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

     

      Atlas Institutional Equity Fund, LP

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

          Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

          3,997,346

       6   

      SHARED VOTING POWER

     

          None (See Item 4)

       7   

      SOLE DISPOSITIVE POWER

     

          3,997,346

       8   

      SHARED DISPOSITIVE POWER

     

          None (See Item 4)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

          3,997,346 (See Item 4)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

          ☐

     

          Not Applicable

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

          5.14%

    12  

      TYPE OF REPORTING PERSON*

     

          PN

    *SEE INSTRUCTIONS BEFORE FILLING OUT.


    CUSIP No. 253031108    Page 10 of 29 Pages

     

      1    

      NAMES OF REPORTING PERSONS

     

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

     

      Atlas Master Fund, Ltd.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

          Cayman

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

          350,494

       6   

      SHARED VOTING POWER

     

          None (See Item 4)

       7   

      SOLE DISPOSITIVE POWER

     

          350,494

       8   

      SHARED DISPOSITIVE POWER

     

          None (See Item 4)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

          350,494 (See Item 4)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

          ☐

     

          Not Applicable

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

          0.45%

    12  

      TYPE OF REPORTING PERSON*

     

          CO

    *SEE INSTRUCTIONS BEFORE FILLING OUT.


    CUSIP No. 253031108    Page 11 of 29 Pages

     

      1    

      NAMES OF REPORTING PERSONS

     

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

     

      Atlas Global Investments, Ltd.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

          Cayman

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

          350,494

       6   

      SHARED VOTING POWER

     

          None (See Item 4)

       7   

      SOLE DISPOSITIVE POWER

     

          350,494

       8   

      SHARED DISPOSITIVE POWER

     

          None (See Item 4)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

          350,494 (See Item 4)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

          ☐

     

          Not Applicable

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

          0.45%

    12  

      TYPE OF REPORTING PERSON*

     

          CO

    *SEE INSTRUCTIONS BEFORE FILLING OUT.


    CUSIP No. 253031108    Page 12 of 29 Pages

     

      1    

      NAMES OF REPORTING PERSONS

     

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

     

      Atlas Global, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

          Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

          350,494

       6   

      SHARED VOTING POWER

     

          None (See Item 4)

       7   

      SOLE DISPOSITIVE POWER

     

          350,494

       8   

      SHARED DISPOSITIVE POWER

     

          None (See Item 4)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

          350,494 (See Item 4)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

          ☐

     

          Not Applicable

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

          0.45%

    12  

      TYPE OF REPORTING PERSON*

     

          PN

    *SEE INSTRUCTIONS BEFORE FILLING OUT.


    CUSIP No. 253031108    Page 13 of 29 Pages

     

      1    

      NAMES OF REPORTING PERSONS

     

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

     

      Balyasny Asset Management L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

          Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

          4,408,952 (See Item 4)

       6   

      SHARED VOTING POWER

     

          None

       7   

      SOLE DISPOSITIVE POWER

     

          4,408,952 (See Item 4)

       8   

      SHARED DISPOSITIVE POWER

     

          None

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

          4,408,952 (See Item 4)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

          ☐

     

          Not Applicable

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

          5.67%

    12  

      TYPE OF REPORTING PERSON*

     

          IA

    *SEE INSTRUCTIONS BEFORE FILLING OUT.


    CUSIP No. 253031108    Page 14 of 29 Pages

     

      1    

      NAMES OF REPORTING PERSONS

     

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

     

      Dmitry Balyasny

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

          United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

          4,408,952 (See Item 4)

       6   

      SHARED VOTING POWER

     

          None

       7   

      SOLE DISPOSITIVE POWER

     

          4,408,952 (See Item 4)

       8   

      SHARED DISPOSITIVE POWER

     

          None

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

          4,408,952 (See Item 4)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

          ☐

     

          Not Applicable

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

          5.67%

    12  

      TYPE OF REPORTING PERSON*

     

          IN

    *SEE INSTRUCTIONS BEFORE FILLING OUT.


    Item 1            (a)    Name of Issuer:

    Dicerna Pharmaceuticals, Inc. (the “Company”)

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    87 Cambridgepark Drive

    Cambridge, MA 02140

    United States

     

    Item 2    (a)

    – (c)    This statement is filed on behalf of the following:

    (1) Atlas Diversified Master Fund, Ltd. is a Cayman corporation (“ADMF”), with its principal business office at c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, George Town, Grand Cayman KY1-1104, Cayman Islands, British West Indies.

    (2) Atlas Diversified Fund, Ltd. is a Cayman corporation (“ADF LTD”), with its principal business office at c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, George Town, Grand Cayman KY1-1104, Cayman Islands, British West Indies. ADF LTD owns 96.88% of the equity interests in ADMF.

    (3) Atlas Diversified Fund, L.P. is a Delaware limited partnership (“ADF LP”), with its principal business office at 444 West Lake Street, 50th Floor, Chicago, IL 60606. ADF LP owns 3.12% of the equity interests in ADMF.

    (4) Atlas Master Fund, Ltd. is a Cayman corporation (“AMF”), with its principal business office at c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, George Town, Grand Cayman KY1-1104, Cayman Islands, British West Indies.

    (5)Atlas Global, LLC is a Delaware limited liability company (“AG”), with its principal business office at 444 West Lake Street, 50th Floor, Chicago, IL 60606. AG owns 3.48% of the equity interests in AMF.

    (6)Atlas Global Investments, Ltd. is a Cayman corporation (“AGI”), with its principal business office at c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, George Town, Grand Cayman KY1-1104, Cayman Islands, British West Indies. AGI owns 96.47% of the equity interests in AMF.

    (7) Atlas Enhanced Master Fund, Ltd. is a Cayman corporation (“AEMF”), with its principal business office at c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, George Town, Grand Cayman KY1-1104, Cayman Islands, British West Indies.

     

    Page 15 of 29 Pages


    (8) Atlas Enhanced Fund, L.P. is a Delaware limited partnership (“AEF LP”), with its principal business office at 444 West Lake Street, 50th Floor, Chicago, IL 60606. AEF LP owns 29.79% of the equity interests in AEMF.

    (9) Atlas Enhanced Fund, Ltd. is a Cayman corporation (“AEF LTD”), with its principal business office at c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, George Town, Grand Cayman KY1-1104, Cayman Islands, British West Indies. AEF LTD owns 57.28% of the equity interests in AEMF.

    (10) Atlas Portable Alpha, LP is a Delaware limited partnership (“APA LP”), with its principal business office at 444 West Lake Street, 50th Floor, Chicago, IL 60606. APA LP owns 4.46% of the equity interests in AEMF.

    (11) Atlas Terra Fund, Ltd. is a Cayman corporation (“ATF LTD”), with its principal business office at c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, George Town, Grand Cayman KY1-1104, Cayman Islands, British West Indies. ATF LTD owns 2.18% of the equity interests in AEMF.

    (12) Atlas Institutional Equity Fund, L.P. is a Delaware limited partnership (“AIEF LP”), with its principal business office at 444 West Lake Street, 50th Floor, Chicago, IL 60606. AIEF LP owns 6.28% of the equity interests in AEMF.

    (13) Balyasny Asset Management L.P. is a Delaware limited partnership (“BAM”), with its principal business office at 444 West Lake Street, 50th Floor, Chicago, IL 60606. BAM is the investment manager to each of ADMF, ADF LTD, ADF LP, AMF, AG, AGI, AEMF, AEF LP, AEF LTD, APA LP, ATF LTD and AIEF LP.

    (14) Dmitry Balyasny, a United States citizen whose business address is 444 West Lake Street, 50th Floor, Chicago, IL 60606. Dmitry Balyasny indirectly controls 100% of the general partner of BAM.

     

      (d)

    Title of Class of Securities:

    Common Stock

     

      (e)

    CUSIP Number: 253031108

     

    Item 3

    If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

    Not Applicable

     

    Page 16 of 29 Pages


    Item 4

    Ownership:

    ADMF

     

      (a)

    Amount Beneficially Owned:

    4,408,952

     

      (b)

    Percent of Class:

    5.67%

     

      (c)

    Number of Shares as to which person has:

     

      (i)

    Sole power to vote or to direct vote:

    4,408,952

     

      (ii)

    Shared power to vote or to direct vote:

    None

     

      (iii)

    Sole power to dispose or direct disposition of:

    4,408,952

     

      (iv)

    Shared power to dispose or to direct disposition of:

    None

    ADF LTD

     

      (a)

    Amount Beneficially Owned:

    By virtue of its ownership of 96.88% of the equity interest in ADMF, ADF LTD may be deemed to beneficially own the 4,408,952 Shares of the Company’s Common Stock beneficially owned by ADMF.

     

      (b)

    Percent of Class:

    5.67%

     

    Page 17 of 29 Pages


      (c)

    Number of Shares as to which person has:

     

      (i)

    Sole power to vote or to direct vote:

    4,408,952

     

      (ii)

    Shared power to vote or to direct vote:

    None

     

      (iii)

    Sole power to dispose or direct disposition of:

    4,408,952

     

      (iv)

    Shared power to dispose or to direct disposition of:

    None

    ADF LP

     

      (a)

    Amount Beneficially Owned:

    By virtue of its ownership of 3.12% of the equity interest in ADMF, ADF LP may be deemed to beneficially own the 4,408,952 Shares of the Company’s Common Stock beneficially owned by ADMF.

     

      (b)

    Percent of Class:

    5.67%

     

      (c)

    Number of Shares as to which person has:

     

      (i)

    Sole power to vote or to direct vote:

    4,408,952

     

      (ii)

    Shared power to vote or to direct vote:

    None

     

      (iii)

    Sole power to dispose or direct disposition of:

    4,408,952

     

    Page 18 of 29 Pages


      (iv)

    Shared power to dispose or to direct disposition of:

    None

    AMF

     

      (a)

    Amount Beneficially Owned:

    By virtue of its ownership of 8.39% of the equity interest in ADMF, AMF may be deemed to beneficially own the 350,494 Shares of the Company’s Common Stock beneficially owned by ADMF.

     

      (b)

    Percent of Class:

    0.45%

     

      (c)

    Number of Shares as to which person has:

     

      (ii)

    Sole power to vote or to direct vote:

    350,494

     

      (ii)

    Shared power to vote or to direct vote:

    None

     

      (iii)

    Sole power to dispose or direct disposition of:

    350,494

     

      (iv)

    Shared power to dispose or to direct disposition of:

    None

    AG

     

      (a)

    Amount Beneficially Owned:

    By virtue of its ownership of 3.48% of the equity interest in AMF, AG may be deemed to beneficially own the 350,494 Shares of the Company’s Common Stock beneficially owned by ADMF.

     

    Page 19 of 29 Pages


      (b)

    Percent of Class:

    0.45%

     

      (c)

    Number of Shares as to which person has:

     

      (i)

    Sole power to vote or to direct vote:

    350,494

     

      (ii)

    Shared power to vote or to direct vote:

    None

     

      (iii)

    Sole power to dispose or direct disposition of:

    350,494

     

      (iv)

    Shared power to dispose or to direct disposition of:

    None

    AGI

     

      (a)

    Amount Beneficially Owned:

    By virtue of its ownership of 96.47% of the equity interest in AMF, AGI may be deemed to beneficially own the 350,494 Shares of the Company’s Common Stock beneficially owned by ADMF.

     

      (b)

    Percent of Class:

    0.45%

     

      (c)

    Number of Shares as to which person has:

     

      (i)

    Sole power to vote or to direct vote:

    350,494

     

      (ii)

    Shared power to vote or to direct vote:

    None

     

      (ii)

    Sole power to dispose or direct disposition of:

    350,494

     

    Page 20 of 29 Pages


      (iv)

    Shared power to dispose or to direct disposition of:

    None

    AEMF

     

      (a)

    Amount Beneficially Owned:

    By virtue of its ownership of 91.61% of the equity interest in ADMF, AEMF may be deemed to beneficially own the 3,997,346 Shares of the Company’s Common Stock beneficially owned by ADMF.

     

      (b)

    Percent of Class:

    5.14%

     

      (c)

    Number of Shares as to which person has:

     

      (i)

    Sole power to vote or to direct vote:

    3,997,346

     

      (ii)

    Shared power to vote or to direct vote:

    None

     

      (iii)

    Sole power to dispose or direct disposition of:

    3,997,346

     

      (iv)

    Shared power to dispose or to direct disposition of:

    None

    AEF LP

     

      (a)

    Amount Beneficially Owned:

    By virtue of its ownership of 29.79% of the equity interest in AEMF, AEF LP may be deemed to beneficially own the 3,997,346 Shares of the Company’s Common Stock beneficially owned by ADMF.

     

    Page 21 of 29 Pages


      (b)

    Percent of Class:

    5.14%

     

      (c)

    Number of Shares as to which person has:

     

      (i)

    Sole power to vote or to direct vote:

    3,997,346

     

      (ii)

    Shared power to vote or to direct vote:

    None

     

      (iii)

    Sole power to dispose or direct disposition of:

    3,997,346

     

      (iv)

    Shared power to dispose or to direct disposition of:

    None

    AEF LTD

     

      (a)

    Amount Beneficially Owned:

    By virtue of its ownership of 57.28% of the equity interest in AEMF, AEF LTD may be deemed to beneficially own the 3,997,346 Shares of the Company’s Common Stock beneficially owned by ADMF.

     

      (b)

    Percent of Class:

    5.14%

     

      (c)

    Number of Shares as to which person has:

     

      (i)

    Sole power to vote or to direct vote:

    3,997,346

     

      (ii)

    Shared power to vote or to direct vote:

    None

     

      (iii)

    Sole power to dispose or direct disposition of:

    3,997,346

     

    Page 22 of 29 Pages


      (iv)

    Shared power to dispose or to direct disposition of:

    None

    APA LP

     

      (a)

    Amount Beneficially Owned:

    By virtue of its ownership of 4.46% of the equity interest in AEMF, APA LP may be deemed to beneficially own the 3,997,346 Shares of the Company’s Common Stock beneficially owned by ADMF.

     

      (b)

    Percent of Class:

    5.14%

     

      (c)

    Number of Shares as to which person has:

     

      (i)

    Sole power to vote or to direct vote:

    3,997,346

     

      (ii)

    Shared power to vote or to direct vote:

    None

     

      (iii)

    Sole power to dispose or direct disposition of:

    3,997,346

     

      (iv)

    Shared power to dispose or to direct disposition of:

    None

     

    Page 23 of 29 Pages


    ATF LTD

     

      (a)

    Amount Beneficially Owned:

    By virtue of its ownership of 2.18% of the equity interest in AEMF, ATF LTD may be deemed to beneficially own the 3,997,346 Shares of the Company’s Common Stock beneficially owned by ADMF.

     

      (b)

    Percent of Class:

    5.14%

     

      (c)

    Number of Shares as to which person has:

     

      (i)

    Sole power to vote or to direct vote:

    3,997,346

     

      (ii)

    Shared power to vote or to direct vote:

    None

     

      (iii)

    Sole power to dispose or direct disposition of:

    3,997,346

     

      (iv)

    Shared power to dispose or to direct disposition of:

    None

    AIEF LP

     

      (a)

    Amount Beneficially Owned:

    By virtue of its ownership of 6.28% of the equity interest in AEMF, AIEF LP may be deemed to beneficially own the 3,997,346 Shares of the Company’s Common Stock beneficially owned by ADMF.

     

      (b)

    Percent of Class:

    5.14%

     

    Page 24 of 29 Pages


      (c)

    Number of Shares as to which person has:

     

      (i)

    Sole power to vote or to direct vote:

    3,997,346

     

      (ii)

    Shared power to vote or to direct vote:

    None

     

      (iii)

    Sole power to dispose or direct disposition of:

    3,997,346

     

      (iv)

    Shared power to dispose or to direct disposition of:

    None

    BAM

     

      (a)

    Amount Beneficially Owned:

    By virtue of its position as investment manager to each of ADMF, ADF LTD, ADF LP, AMF, AG, AGI, AEMF, AEF LP, AEF LTD, APA LP, ATF LTD and AIEF LP, BAM may be deemed to beneficially own the 4,408,952 Shares of the Company’s Common Stock beneficially owned by ADMF, ADF LTD, ADF LP, AMF, AG, AGI, AEMF, AEF LP, AEF LTD, APA LP, ATF LTD and AIEF LP.

     

      (b)

    Percent of Class:

    5.67%

     

      (c)

    Number of Shares as to which person has:

     

      (i)

    Sole power to vote or to direct vote:

    4,408,952

     

      (ii)

    Shared power to vote or to direct vote:

    None

     

    Page 25 of 29 Pages


      (iii)

    Sole power to dispose or direct disposition of:

    4,408,952

     

      (iv)

    Shared power to dispose or to direct disposition of:

    None

    Dmitry Balyasny

     

      (a)

    Amount Beneficially Owned:

    By virtue of his position as the sole control person for BAM, Mr. Balyasny may be deemed to beneficially own the 4,408,952 Shares of the Company’s Common Stock beneficially owned by BAM.

     

      (b)

    Percent of Class:

    5.67%

     

      (c)

    Number of Shares as to which person has:

     

      (i)

    Sole power to vote or to direct vote:

    4,408,952

     

      (ii)

    Shared power to vote or to direct vote:

    None

     

      (iii)

    Sole power to dispose or direct disposition of:

    4,408,952

     

      (iv)

    Shared power to dispose or to direct disposition of:

    None

     

    Item 5

    Ownership of Five Percent or Less of a Class:

    Applicable

     

    Item 6

    Ownership of More than Five Percent on Behalf of Another Person:

    Not Applicable

     

    Page 26 of 29 Pages


    Item 7

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:

    Not Applicable

     

    Item 8

    Identification and Classification of Members of the Group:

    Not Applicable

     

    Item 9

    Notice of Dissolution of Group:

    Not Applicable

     

    Item 10

    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Page 27 of 29 Pages


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: December 3, 2021

     

    ATLAS DIVERSIFIED MASTER FUND, LTD.

     

    By: /s/ Scott Schroeder

    Scott Schroeder

    Authorized Signatory

      

    ATLAS MASTER FUND, LTD.

     

    By: /s/ Scott Schroeder

           Scott Schroeder

           Authorized Signatory

    ATLAS DIVERSIFIED FUND, LTD.

     

    By: /s/ Scott Schroeder

           Scott Schroeder

           Authorized Signatory

      

    ATLAS DIVERSIFIED FUND, L.P.

     

    By: /s/ Scott Schroeder

           Scott Schroeder

           Authorized Signatory

    ATLAS GLOBAL, LLC

     

    By: /s/ Scott Schroeder

           Scott Schroeder

           Authorized Signatory

      

    ATLAS GLOBAL INVESTMENTS, LTD.

     

    By: /s/ Scott Schroeder

           Scott Schroeder

           Authorized Signatory

    ATLAS ENHANCED MASTER FUND, LTD.

     

    By: /s/ Scott Schroeder

           Scott Schroeder

           Authorized Signatory

      

    ATLAS ENHANCED FUND, L.P.

     

    By: /s/ Scott Schroeder

           Scott Schroeder

           Authorized Representative

    ATLAS PORTABLE ALPHA, LP

     

    By: /s/ Scott Schroeder

           Scott Schroeder

           Authorized Signatory

      

    ATLAS TERRA FUND, LTD.

     

    By: /s/ Scott Schroeder

           Scott Schroeder

           Authorized Signatory

     

    Page 28 of 29 Pages


    ATLAS INSTITUTIONAL EQUITY FUND, L.P.

     

    By: /s/ Scott Schroeder

           Scott Schroeder

           Authorized Signatory

      

    BALYASNY ASSET MANAGEMENT L.P.

     

    By: /s/ Scott Schroeder

           Scott Schroeder

           Authorized Signatory

    DMITRY BALYASNY

     

    By: /s/ Scott Schroeder

           Scott Schroeder

           Authorized Representative

      

     

    Page 29 of 29 Pages

    Get the next $DRNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DRNA

    DatePrice TargetRatingAnalyst
    12/9/2021$28.00 → $38.25Buy → Neutral
    Chardan Capital
    11/19/2021$30.00 → $38.25Outperform → Sector Perform
    RBC Capital
    11/18/2021$32.00 → $38.25Buy → Neutral
    HC Wainwright & Co.
    8/11/2021$36.00 → $25.00Buy → Neutral
    Goldman Sachs
    8/10/2021$34.00 → $28.00Buy
    Chardan Capital
    8/10/2021$38.00 → $32.00Buy
    HC Wainwright & Co.
    8/9/2021$32.00Buy → Neutral
    Citigroup
    8/6/2021$35.00 → $30.00Outperform
    RBC Capital
    More analyst ratings

    $DRNA
    Leadership Updates

    Live Leadership Updates

    See more
    • Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

      SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a

      9/24/24 8:00:00 AM ET
      $ALGS
      $HAE
      $NVO
      $PLRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical/Dental Instruments
      Biotechnology: Pharmaceutical Preparations
    • Dicerna Announces New Executive Leadership Appointments

      – Rob Ciappenelli Appointed Chief Strategy Officer and Marc Abrams, Ph.D., Promoted to Senior Vice President of Discovery Research – – Kristen Sheppard, Esq., Joins Company as Senior Vice President of Investor Relations and Corporate Communications – Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the appointment of Rob Ciappenelli as Chief Strategy Officer, the promotion of Marc Abrams, Ph.D., to Senior Vice President, Discovery Research and the addition of Kristen Sheppard, Esq., to Dicerna's executive leadership team as Senior Vice President, Investor Rela

      9/22/21 7:30:00 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 23,350 shares of common stock and 5,675 restricted stock units (“RSUs”) to be distributed among three new employees with a grant date of Jan. 4, 2021 (the “Inducement Grants”). The stock options approved under the Inducement Grants were issued pursuant to Dicerna’s 2016 Inducement Plan and have an exercise price per share equal to $22.07

      1/4/21 5:30:00 PM ET
      $DRNA
      Major Pharmaceuticals
      Health Care

    $DRNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Dicerna Pharmaceuticals downgraded by Chardan Capital with a new price target

      Chardan Capital downgraded Dicerna Pharmaceuticals from Buy to Neutral and set a new price target of $38.25 from $28.00 previously

      12/9/21 4:59:39 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Dicerna Pharmaceuticals downgraded by RBC Capital with a new price target

      RBC Capital downgraded Dicerna Pharmaceuticals from Outperform to Sector Perform and set a new price target of $38.25 from $30.00 previously

      11/19/21 5:44:25 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Dicerna Pharmaceuticals downgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. downgraded Dicerna Pharmaceuticals from Buy to Neutral and set a new price target of $38.25 from $32.00 previously

      11/18/21 11:53:19 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care

    $DRNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Koppel Adam closing all direct ownership in the company

      4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)

      12/29/21 4:43:55 PM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Zeng Ling closing all direct ownership in the company

      4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)

      12/29/21 4:22:27 PM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Weissman James B closing all direct ownership in the company

      4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)

      12/29/21 4:22:10 PM ET
      $DRNA
      Major Pharmaceuticals
      Health Care

    $DRNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $DRNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $DRNA
    SEC Filings

    See more
    • SEC Form SC 13G filed by Dicerna Pharmaceuticals, Inc.

      SC 13G - Dicerna Pharmaceuticals Inc (0001399529) (Subject)

      12/3/21 6:09:54 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Dicerna Pharmaceuticals Inc (0001399529) (Subject)

      2/12/21 3:36:29 PM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Dicerna Pharmaceuticals Inc (0001399529) (Subject)

      2/12/21 10:01:42 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

      SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a

      9/24/24 8:00:00 AM ET
      $ALGS
      $HAE
      $NVO
      $PLRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical/Dental Instruments
      Biotechnology: Pharmaceutical Preparations
    • Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition

      Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. ((Dicerna, NASDAQ:DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk's cash tender offer for Dicerna, Novo Nordisk has today acquired all outstanding shares of common stock of Dicerna at a price of USD 38.25 per share in cash, without interest and less any applicable tax withholding. Novo Nordisk has been advised by the depositary for the tender offer that a total of approximately 64,946,526 shares of Dicerna's common stock were validly tendered and not validly withdrawn in the tender offer as of the tender offer expiration at 5.00 pm EST on 27 December 2021,

      12/28/21 9:04:00 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna

      Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in connection with Novo Nordisk's cash tender offer for Dicerna expired at 11:59 p.m., Eastern Time, on December 24, 2021. As previously announced on November 18, 2021, Novo Nordisk commenced a cash tender offer to purchase all outstanding shares of Dicerna common stock for $38.25 per share in cash, without interest and subject to any withholding of taxes. The expiration of the HSR waiting period satisfies one of the conditions necessary for the consummation of the tender offer. Other conditions remain to be satisfied, inclu

      12/25/21 8:00:00 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form 15-12B filed by Dicerna Pharmaceuticals, Inc.

      15-12B - Dicerna Pharmaceuticals Inc (0001399529) (Filer)

      1/10/22 4:59:18 PM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.

      EFFECT - Dicerna Pharmaceuticals Inc (0001399529) (Filer)

      1/3/22 12:15:12 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.

      EFFECT - Dicerna Pharmaceuticals Inc (0001399529) (Filer)

      1/3/22 12:15:18 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care

    $DRNA
    Financials

    Live finance-specific insights

    See more
    • Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition

      Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. ((Dicerna, NASDAQ:DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk's cash tender offer for Dicerna, Novo Nordisk has today acquired all outstanding shares of common stock of Dicerna at a price of USD 38.25 per share in cash, without interest and less any applicable tax withholding. Novo Nordisk has been advised by the depositary for the tender offer that a total of approximately 64,946,526 shares of Dicerna's common stock were validly tendered and not validly withdrawn in the tender offer as of the tender offer expiration at 5.00 pm EST on 27 December 2021,

      12/28/21 9:04:00 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update

      – Reported Positive Top-Line Data From Pivotal PHYOX™2 Clinical Trial of Nedosiran Investigational GalXC™ RNAi Therapy for Treatment of Primary Hyperoxaluria (PH) – – Initiated Phase 1 Clinical Trial of DCR-AUD for the Treatment of Alcohol Use Disorder (AUD) – – Company Plans to Unveil First GalXC-Plus™ Extrahepatic Target in Early 2022 – – Cash Runway Extends Into 2025 – – Company to Host Conference Call Today at 8:30 a.m. ET – Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported its financial results for the third quarter ended September 30, 2021 and provided a business update. "We had a

      11/9/21 7:30:00 AM ET
      $DRNA
      Major Pharmaceuticals
      Health Care
    • Dicerna to Report Third Quarter 2021 Financial Results on Nov. 9, 2021

      Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2021 financial results before market open on Tuesday, Nov. 9, 2021. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live and will be available from the "Investors & Media" section of the Dicerna website, www.dicerna.com. The webcast will also be archived on the Company's website. The conference call can be accessed by dialing (855) 4

      11/2/21 4:05:00 PM ET
      $DRNA
      Major Pharmaceuticals
      Health Care